Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Antibody / Recombinant Antibody

Anti-PTPN11 Antibody (R3R22)

Catalog #:   RHG07502 Specific References (50) DATASHEET
Host species: Mouse
Isotype: IgG1
Applications: ELISA, FCM, IF, IHC
Accession: Q06124
Overview

Catalog No.

RHG07502

Species reactivity

Human

Host species

Mouse

Isotype

IgG1

Clonality

Monoclonal

Tested applications

ELISA: 1:10000, FCM: 1:200-1:400, IF: 1:200-1:1000, IHC: 1:200-1:1000

Target

Tyrosine-protein phosphatase non-receptor type 11, Protein-tyrosine phosphatase 1D, PTP-2C, Shp2, SHP-2, SH-PTP3, Protein-tyrosine phosphatase 2C, PTP2C, PTP-1D, PTPN11, SHPTP2, SH-PTP2

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

Q06124

Applications

ELISA, FCM, IF, IHC

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 0.05% Sodium Azide.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

R3R22

Data Image
  • Flow Cytometry
    Flow cytometric analysis of HepG2 cells using PTPN11 mouse mAb (green) and negative control (red).
  • Immunofluorescence
    Immunofluorescence analysis of HeLa cells using PTPN11 mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye.
  • Immunohistochemical
    Immunohistochemical analysis of paraffin-embedded human breast cancer tissues using PTPN11 mouse mAb with DAB staining.
  • Immunohistochemical
    Immunohistochemical analysis of paraffin-embedded human rectum cancer tissues using PTPN11 mouse mAb with DAB staining.
References

Siglec6 CAR T cells suppressed progression of AML via inhibiting Siglec6 and SHP2 induced Src and ERK signaling activation., PMID:40436895

Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 Inhibitor JAB-3312., PMID:40304209

Ras-MAPK pathway in patients with lupus nephritis., PMID:40102014

Elucidating the pharmacological foundations and mechanisms of the Sihai Shuyu formula in treating Graves' disease through integrated serum metabolomics and network pharmacology with molecular docking techniques., PMID:39950029

T Lymphocyte-Specific Deletion of SHP1 and SHP2 Promotes Activation-Induced Cell Death of CD4+ T Cells and Impairs Antitumor Response., PMID:39803505

Neuropathology and epilepsy surgery - 2024 update., PMID:38532826

Shp2 Deficiency in Kupffer Cells and Hepatocytes Aggravates Hepatocarcinogenesis by Recruiting Non-Kupffer Macrophages., PMID:36828281

Early Triple-Negative Breast Cancers in a Singapore Cohort Exhibit High PIK3CA Mutation Rates Associated With Low PD-L1 Expression., PMID:36788078

Endocrine system involvement in patients with RASopathies: A case series., PMID:36483002

GH Responsiveness in Children With Noonan Syndrome Compared to Turner Syndrome., PMID:34858328

Genomic data from NSCLC tumors reveals correlation between SHP-2 activity and PD-L1 expression and suggests synergy in combining SHP-2 and PD-1/PD-L1 inhibitors., PMID:34437586

Acute disseminated encephalomyelitis in a patient with Noonan syndrome: A rare autoinflammatory complication or coincidence?, PMID:34242782

SHP2 Targets ITK Downstream of PD-1 to Inhibit T Cell Function., PMID:33624224

Patient-derived xenograft (PDX) models of colorectal carcinoma (CRC) as a platform for chemosensitivity and biomarker analysis in personalized medicine., PMID:33212364

Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling., PMID:33046519

Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma., PMID:32816890

Bacteroides fragilis alleviates the symptoms of lupus nephritis via regulating CD1d and CD86 expressions in B cells., PMID:32721450

PD-1 and BTLA regulate T cell signaling differentially and only partially through SHP1 and SHP2., PMID:32437509

Blocking interaction between SHP2 and PD-1 denotes a novel opportunity for developing PD-1 inhibitors., PMID:32391629

Leukocyte immunoglobulin-like receptor B4 protects against cardiac hypertrophy via SHP-2-dependent inhibition of the NF-κB pathway., PMID:32280997

1H, 13C, 15N chemical shift assignments of SHP2 SH2 domains in complex with PD-1 immune-tyrosine motifs., PMID:32236803

Identification, recombinant expression and immunological study of Lja-SHP2 in Lampetra japonica., PMID:32102775

Shp2 activation in bone marrow microenvironment mediates the drug resistance of B-cell acute lymphoblastic leukemia through enhancing the role of VCAM-1/VLA-4., PMID:31978797

PTPN11 (SHP2) Is Indispensable for Growth Factors and Cytokine Signal Transduction During Bovine Oocyte Maturation and Blastocyst Development., PMID:31635340

Identification and Characterization of Post-activated B Cells in Systemic Autoimmune Diseases., PMID:31616406

Quantitative Interactomics in Primary T Cells Provides a Rationale for Concomitant PD-1 and BTLA Coinhibitor Blockade in Cancer Immunotherapy., PMID:31189114

Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma., PMID:30742119

Genomic alterations associated with HER2+ breast cancer risk and clinical outcome in response to trastuzumab., PMID:30535550

LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration., PMID:30333625

Uncoupling ITIM receptor G6b-B from tyrosine phosphatases Shp1 and Shp2 disrupts murine platelet homeostasis., PMID:29891536

SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo., PMID:29808006

Association between single-nucleotide polymorphisms and adverse events in nivolumab-treated non-small cell lung cancer patients., PMID:29695768

Too many targets, not enough patients: rethinking neuroblastoma clinical trials., PMID:29632319

Affinity purification mass spectrometry analysis of PD-1 uncovers SAP as a new checkpoint inhibitor., PMID:29282323

Antibody blockade of CLEC12A delays EAE onset and attenuates disease severity by impairing myeloid cell CNS infiltration and restoring positive immunity., PMID:28578388

Targeted nanoconjugate co-delivering siRNA and tyrosine kinase inhibitor to KRAS mutant NSCLC dissociates GAB1-SHP2 post oncogene knockdown., PMID:27530552

Inhibition of SHP2 ameliorates the pathogenesis of systemic lupus erythematosus., PMID:27183387

Rare Helicobacter pylori Infection May Explain Low Stomach Cancer Incidence: Ecological Observations in Bali, Indonesia., PMID:27039823

Changes in Gab2 phosphorylation and interaction partners in response to interleukin (IL)-2 stimulation in T-lymphocytes., PMID:27025927

The adhesion molecule PECAM-1 enhances the TGF-β-mediated inhibition of T cell function., PMID:26956486

SIRPα1-SHP2 Interaction Regulates Complete Freund Adjuvant-Induced Inflammatory Pain via Src-Dependent GluN2B Phosphorylation in Rats., PMID:26720617

Expression and clinical significance of tyrosine phosphatase SHP2 in thyroid carcinoma., PMID:26622699

NOX4-dependent Hydrogen peroxide promotes shear stress-induced SHP2 sulfenylation and eNOS activation., PMID:26427883

CD99 inhibits CD98-mediated β1 integrin signaling through SHP2-mediated FAK dephosphorylation., PMID:26172215

Do Genetic Susceptibility Variants Associate with Disease Severity in Early Active Rheumatoid Arthritis?, PMID:25979711

STAT1-Induced HLA Class I Upregulation Enhances Immunogenicity and Clinical Response to Anti-EGFR mAb Cetuximab Therapy in HNC Patients., PMID:25972070

Irreversible dual inhibitory mode: the novel Btk inhibitor PLS-123 demonstrates promising anti-tumor activity in human B-cell lymphoma., PMID:25944695

The Killer Cell Ig-like Receptor 2DL4 Expression in Human Mast Cells and Its Potential Role in Breast Cancer Invasion., PMID:25735953

Rapidly progressive hypertrophic cardiomyopathy in an infant with Noonan syndrome with multiple lentigines: palliative treatment with a rapamycin analog., PMID:25708222

Autoimmune liver disease in Noonan Syndrome., PMID:25595571

Datasheet

Document Download

Anti-PTPN11 Antibody (R3R22).pdf

 

$ 220
Product specifications
50 μg 220 100 μg 350

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-PTPN11 Antibody (R3R22) [RHG07502]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only